Reported Earlier, Takeda Announces U.S. FDA Approval Of ENTYVIO Subcutaneous Administration For Maintenance Therapy In Moderately To Severely Active Crohn's Disease
Reported Earlier, Takeda Announces U.S. FDA Approval Of ENTYVIO Subcutaneous Administration For Maintenance Therapy In Moderately To Severely Active Crohn's Disease
此前報道，武田宣佈美國食品藥品管理局批准ENTYVIO皮下給藥用於中度至重度活性克羅恩病的維持治療
ENTYVIO is Now Available in the U.S. in Both IV and Subcutaneous Administrations for Maintenance Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
ENTYVIO現已在美國提供靜脈和皮下給藥兩種形式，用於中度至重度活動性潰瘍性結腸炎或克羅恩氏病的成年人的維持性治療